Taking Advantage of the New Purple Book Patent Requirements for Biologics

Published date26 April 2021
Subject MatterFDA,Patents,Life Sciences,Biosimilars,Biologics,Pharmaceutical Patents,IP License,Purple Book,Intellectual Property Protection,Pharmaceutical Industry,Small and Medium-Sized Enterprises (SMEs)
AuthorJeffrey Gargano,Zachary Miller
Law FirmMorgan Lewis

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT